CA3048591A1 - Polymorphs and solid forms of (s)-2-((2-((s)-4-(difluoromethyl)-2-oxooxazolidin-3-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)amino)propanamide, and methods of production - Google Patents

Polymorphs and solid forms of (s)-2-((2-((s)-4-(difluoromethyl)-2-oxooxazolidin-3-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)amino)propanamide, and methods of production Download PDF

Info

Publication number
CA3048591A1
CA3048591A1 CA3048591A CA3048591A CA3048591A1 CA 3048591 A1 CA3048591 A1 CA 3048591A1 CA 3048591 A CA3048591 A CA 3048591A CA 3048591 A CA3048591 A CA 3048591A CA 3048591 A1 CA3048591 A1 CA 3048591A1
Authority
CA
Canada
Prior art keywords
polymorph
crystalline
gdc
ray powder
theta
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3048591A
Other languages
English (en)
French (fr)
Inventor
Paroma CHAKRAVARTY
Chong Han
Sean M. Kelly
Karthik Nagapudi
Scott Savage
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=62492573&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA3048591(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of CA3048591A1 publication Critical patent/CA3048591A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
CA3048591A 2017-04-28 2018-04-26 Polymorphs and solid forms of (s)-2-((2-((s)-4-(difluoromethyl)-2-oxooxazolidin-3-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)amino)propanamide, and methods of production Pending CA3048591A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762491812P 2017-04-28 2017-04-28
US62/491,812 2017-04-28
PCT/EP2018/060820 WO2018197653A1 (en) 2017-04-28 2018-04-26 Polymorphs and solid forms of (s)-2-((2-((s)-4-(difluoromethyl)-2-oxooxazolidin-3-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)amino)propanamide, and methods of production

Publications (1)

Publication Number Publication Date
CA3048591A1 true CA3048591A1 (en) 2018-11-01

Family

ID=62492573

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3048591A Pending CA3048591A1 (en) 2017-04-28 2018-04-26 Polymorphs and solid forms of (s)-2-((2-((s)-4-(difluoromethyl)-2-oxooxazolidin-3-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)amino)propanamide, and methods of production

Country Status (13)

Country Link
US (4) US20180339997A1 (enExample)
EP (2) EP3615541B1 (enExample)
JP (2) JP6998969B2 (enExample)
KR (1) KR102342776B1 (enExample)
CN (1) CN110650963B (enExample)
AU (1) AU2018259089B2 (enExample)
CA (1) CA3048591A1 (enExample)
ES (1) ES3027566T3 (enExample)
IL (3) IL298518B2 (enExample)
MX (1) MX394540B (enExample)
PL (1) PL3615541T3 (enExample)
TW (1) TWI826373B (enExample)
WO (1) WO2018197653A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111909173B (zh) 2015-07-02 2025-03-04 豪夫迈·罗氏有限公司 苯并氧氮杂䓬噁唑烷酮化合物及其使用方法
PL3851441T3 (pl) 2016-12-15 2023-11-06 F. Hoffmann-La Roche Ag Proces otrzymywania (S)-2-((2-((S)-4-(difluorometylo)-2-oksooksazolidyn-3-ylo)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oksazepin-9-ylo)amino)propanamidu
IL298518B2 (en) * 2017-04-28 2025-05-01 Hoffmann La Roche Polymorphs and solid forms of (S)–2–((2–((S–4–(difluoromethyl)–2–oxoxazolidin-3–yl)–5,6–dihydrobenzo[F]imidazo[1,2–D][1,4]oxazepin-9–yl)amino)propanamide and methods of preparation
JP7365073B2 (ja) * 2019-05-21 2023-10-19 ジァンスー フォアフロント ファーマシューティカル カンパニー，リミテッド トレプロスチニルナトリウムの新規な結晶形および製造方法
CA3144791A1 (en) * 2019-07-07 2021-01-14 Olema Pharmaceuticals, Inc. Regimens of estrogen receptor antagonists
WO2021041348A1 (en) 2019-08-26 2021-03-04 Arvinas Operations, Inc. Methods of treating breast cancer with tetrahydronaphthalene derivatives as estrogen receptor degraders
CN112830935B (zh) * 2019-11-25 2023-12-22 上海翰森生物医药科技有限公司 含三并环类衍生物自由碱的晶型及其药物组合物
CN113227101B (zh) * 2019-11-25 2024-10-11 上海翰森生物医药科技有限公司 含三并环类衍生物的盐或晶型及其药物组合物
TWI801730B (zh) * 2020-04-07 2023-05-11 神雲科技股份有限公司 具系統設定資料同步功能的伺服器
WO2022161347A1 (zh) * 2021-01-29 2022-08-04 南京明德新药研发有限公司 三并环类化合物及其应用
TW202440096A (zh) 2023-03-24 2024-10-16 美商亞文納營運公司 雌激素受體降解劑之給藥方案

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6274327B1 (en) 1992-04-13 2001-08-14 Ludwig Institute For Cancer Research Polypeptides having kinase activity, their preparation and use
US5846824A (en) 1994-02-07 1998-12-08 Ludwig Institute For Cancer Research Polypeptides having kinase activity, their preparation and use
GB9208135D0 (en) 1992-04-13 1992-05-27 Ludwig Inst Cancer Res Polypeptides having kinase activity,their preparation and use
TWI423980B (zh) 2009-09-28 2014-01-21 Hoffmann La Roche 苯并氧氮呯ｐｉ３ｋ抑制劑化合物及使用方法
JP5808818B2 (ja) 2010-11-25 2015-11-10 ラツィオファーム・ゲーエムベーハー アファチニブの新規塩及び多形形態
US9266903B2 (en) 2013-12-16 2016-02-23 Genentech, Inc. Polymorphs of 2-(4-(2-(1-isopropyl-3-methyl-1H-1,2,4-triazole-5-yl)-5,6-dihydrobenzo[F]imidazo [1,2-D][1,4]oxazepin-9-yl)-1H-pyrazol-1-yl)-2-methylpropanamide, methods of production, and pharmaceutical uses thereof
CN111909173B (zh) 2015-07-02 2025-03-04 豪夫迈·罗氏有限公司 苯并氧氮杂䓬噁唑烷酮化合物及其使用方法
PL3851441T3 (pl) 2016-12-15 2023-11-06 F. Hoffmann-La Roche Ag Proces otrzymywania (S)-2-((2-((S)-4-(difluorometylo)-2-oksooksazolidyn-3-ylo)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oksazepin-9-ylo)amino)propanamidu
IL298518B2 (en) 2017-04-28 2025-05-01 Hoffmann La Roche Polymorphs and solid forms of (S)–2–((2–((S–4–(difluoromethyl)–2–oxoxazolidin-3–yl)–5,6–dihydrobenzo[F]imidazo[1,2–D][1,4]oxazepin-9–yl)amino)propanamide and methods of preparation

Also Published As

Publication number Publication date
WO2018197653A1 (en) 2018-11-01
US20200399286A1 (en) 2020-12-24
EP4534148A2 (en) 2025-04-09
US20180339997A1 (en) 2018-11-29
US12410189B2 (en) 2025-09-09
IL267464B2 (en) 2023-05-01
IL298518B2 (en) 2025-05-01
EP3615541C0 (en) 2025-03-19
MX394540B (es) 2025-03-21
US20210094970A1 (en) 2021-04-01
JP6998969B2 (ja) 2022-02-10
AU2018259089B2 (en) 2022-05-12
AU2018259089A1 (en) 2019-07-04
JP2020517713A (ja) 2020-06-18
TWI826373B (zh) 2023-12-21
US11591345B2 (en) 2023-02-28
IL298518B1 (en) 2025-01-01
AU2018259089A9 (en) 2019-10-10
WO2018197653A9 (en) 2019-09-19
CN110650963A (zh) 2020-01-03
US20230167128A1 (en) 2023-06-01
KR102342776B1 (ko) 2021-12-23
BR112019013292A2 (pt) 2019-12-10
EP4534148A3 (en) 2025-05-21
EP3615541A1 (en) 2020-03-04
PL3615541T3 (pl) 2025-06-23
TW201843160A (zh) 2018-12-16
ES3027566T3 (en) 2025-06-16
CN110650963B (zh) 2022-09-27
JP2021181446A (ja) 2021-11-25
IL317762A (en) 2025-02-01
US11028100B2 (en) 2021-06-08
IL298518A (en) 2023-01-01
EP3615541B1 (en) 2025-03-19
KR20190133724A (ko) 2019-12-03
MX2019012507A (es) 2019-12-19
IL267464A (en) 2019-08-29
IL267464B1 (en) 2023-01-01

Similar Documents

Publication Publication Date Title
US12410189B2 (en) Polymorphs and solid forms of (S)-2-2((2-((S)-4-(difluoromethyl)-2-oxooxazolidin-3-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9- yl)amino)propanamide, and methods of production
CA2900322C (en) Solid forms of the selective cdk4/6 inhibitor compound acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-8h-pyrido[2,3-d]pyrimidin-7-one
US20180208596A1 (en) Solid Forms and Formulations of Imidazopyrazine Compound
AU2018372180B2 (en) Polymorphs and solid forms of a pyrimidinylamino-pyrazole compound, and methods of production
TWI638818B (zh) ２－（４－（２－（１－異丙基－３－甲基－１ｈ－１，２，４－三唑－５－基）－５，６－二氫苯并［ｆ］咪唑并［１，２－ｄ］［１，４］氧氮呯－９－基）－１ｈ－吡唑－１－基）－２－甲基丙醯胺之多晶型、製造方法及醫藥用途
HK40124018A (en) Polymorphs and solid forms of (s)-2-((2-((s)-4-(difluoromethyl)-2-oxooxazolidin-3-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)amino)propanamide, and methods of production
BR112019013292B1 (pt) Polimorfos anidratos cristalinos, polimorfo triidrato cristalino, composições farmacêuticas, processo para preparar um polimorfo cristalino e uso de um polimorfo cristalino
HK40020487A (en) Polymorphs and solid forms of gdc-0077, and methods of production thereof
HK40020487B (en) Polymorphs and solid forms of gdc-0077, and methods of production thereof
HK1223101B (en) Polymorphs of gdc-0032, methods of production, and pharmaceutical uses thereof
HK40003818A (en) Polymorphs of gdc-0032, methods of production, and pharmaceutical uses thereof

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220926

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250110

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD

Year of fee payment: 7

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250324

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250410

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250410

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250718

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250718

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250808

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260120

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260127

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 8TH ANNIV.) - STANDARD

Year of fee payment: 8

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260320

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260320

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-4-4-D10-D00-D164 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: RESPONSE TO NOTICE OF ALLOWANCE

Effective date: 20260527

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-2-4-D10-D22-D143 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRE-GRANT

Effective date: 20260604

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260604